MA55069A - Nouvelles protéines de fusion spécifique à cd137 et gpc3 - Google Patents

Nouvelles protéines de fusion spécifique à cd137 et gpc3

Info

Publication number
MA55069A
MA55069A MA055069A MA55069A MA55069A MA 55069 A MA55069 A MA 55069A MA 055069 A MA055069 A MA 055069A MA 55069 A MA55069 A MA 55069A MA 55069 A MA55069 A MA 55069A
Authority
MA
Morocco
Prior art keywords
gpc3
fusion proteins
proteins specific
new fusion
new
Prior art date
Application number
MA055069A
Other languages
English (en)
Inventor
Aiba Rachida Siham Bel
Birgit Bossenmaier
Eva-Maria Hansbauer
Thomas Jaquin
Shane Olwill
Janet Peper-Gabriel
Corinna Schlosser
Original Assignee
Pieris Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pieris Pharmaceuticals Gmbh filed Critical Pieris Pharmaceuticals Gmbh
Publication of MA55069A publication Critical patent/MA55069A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA055069A 2019-02-26 2020-02-25 Nouvelles protéines de fusion spécifique à cd137 et gpc3 MA55069A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19000100 2019-02-26

Publications (1)

Publication Number Publication Date
MA55069A true MA55069A (fr) 2022-01-05

Family

ID=65685094

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055069A MA55069A (fr) 2019-02-26 2020-02-25 Nouvelles protéines de fusion spécifique à cd137 et gpc3

Country Status (13)

Country Link
US (1) US20220153864A1 (fr)
EP (1) EP3931209A1 (fr)
JP (1) JP7476219B2 (fr)
KR (1) KR20210133254A (fr)
CN (1) CN113474359A (fr)
AU (1) AU2020229436A1 (fr)
BR (1) BR112021016829A2 (fr)
CA (1) CA3124441A1 (fr)
IL (1) IL284687A (fr)
MA (1) MA55069A (fr)
MX (1) MX2021010039A (fr)
SG (1) SG11202106353VA (fr)
WO (1) WO2020173897A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113939307A (zh) * 2019-03-29 2022-01-14 皮里斯制药有限公司 脂质运载蛋白突变蛋白的吸入施用
EP4319810A2 (fr) * 2021-04-05 2024-02-14 Cytovia Therapeutics, Llc. Anticorps bispécifiques ciblant nkp46 et gpc3 et leurs méthodes d'utilisation
AU2022260298A1 (en) * 2021-04-23 2023-11-02 Shanghai Henlius Biotech, Inc. Anti-gpc3 antibodies, multispecific antibodies and methods of use
JP2024522078A (ja) * 2021-05-21 2024-06-11 ベイジーン スウィッツァーランド ゲーエムベーハー 抗ｇｐｃ３及び抗ｃｄ１３７多重特異性抗体ならびにそれらの使用方法
WO2023036043A1 (fr) * 2021-09-09 2023-03-16 广东东阳光药业有限公司 Molécule de liaison anti-cancéreuse et son utilisation
CN113956344A (zh) * 2021-10-14 2022-01-21 江南大学 一种新型治疗肝癌的fgf类似物及其应用
CN113912699A (zh) * 2021-10-14 2022-01-11 江南大学 一种新型治疗乳腺癌的fgf类似物及其应用
CN116640224A (zh) * 2022-02-16 2023-08-25 北京免疫方舟医药科技有限公司 Cd137抗体和cd40l的融合蛋白及其应用
WO2023180523A1 (fr) 2022-03-24 2023-09-28 Pieris Pharmaceuticals Gmbh Procédé de purification de protéines de fusion

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DK1136556T3 (da) 1991-11-25 2005-10-03 Enzon Inc Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US6080560A (en) 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (fr) 1998-03-31 1999-09-30 Hemosol Inc. Complexes d'amidon hydroxyethyles d'hemoglobine
AU767131B2 (en) 1998-06-08 2003-10-30 F. Hoffmann-La Roche Ag Use of PEG-IFN-alpha and ribavirin for the treatment of chronic hepatitis C
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
JP4336771B2 (ja) 2001-03-09 2009-09-30 モルフォシス アーゲー 血清アルブミン結合部分
AU2003275958A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
US7892827B2 (en) 2004-11-26 2011-02-22 Pieris Ag Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
CA2622441A1 (fr) 2005-09-27 2007-04-05 Amunix, Inc. Produits pharmaceutiques proteiques et utilisations de ceux-ci
JP5608368B2 (ja) 2006-08-01 2014-10-15 ピエリス アーゲー 涙リポカリンの突然変異タンパク質およびそれを得るための方法
NZ729044A (en) 2010-09-09 2020-07-31 Pfizer 4-1bb binding molecules
WO2013174783A1 (fr) 2012-05-23 2013-11-28 Pieris Ag Mutéines de lipocaline avec affinité de liaison pour le glypican-3 (gpc-3) et utilisation de mutéines de lipocaline pour la délivrance spécifique de la cible aux cellules exprimant le gpc-3
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
SG11201708339QA (en) 2015-05-04 2017-11-29 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
CN114316067A (zh) * 2015-05-04 2022-04-12 皮里斯制药有限公司 抗癌融合多肽
WO2016184875A1 (fr) 2015-05-18 2016-11-24 Pieris Pharmaceuticals Gmbh Mutéines de la lipocaline 2 humaine avec affinité pour glypican-3 (gpc3)
RU2754466C2 (ru) 2015-05-18 2021-09-02 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Слитый полипептид с противораковой активностью
WO2018087108A1 (fr) 2016-11-09 2018-05-17 Pieris Pharmaceuticals Gmbh Protéines spécifiques de cd137
US20200040084A1 (en) * 2017-01-06 2020-02-06 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs
EP3638700A4 (fr) 2017-06-14 2021-04-21 Dingfu Biotarget Co., Ltd Hétérodimère protéique et utilisation de celui-ci

Also Published As

Publication number Publication date
MX2021010039A (es) 2021-09-21
JP7476219B2 (ja) 2024-04-30
WO2020173897A1 (fr) 2020-09-03
JP2022523524A (ja) 2022-04-25
AU2020229436A1 (en) 2021-07-01
EP3931209A1 (fr) 2022-01-05
US20220153864A1 (en) 2022-05-19
IL284687A (en) 2021-08-31
BR112021016829A2 (pt) 2021-10-19
KR20210133254A (ko) 2021-11-05
CA3124441A1 (fr) 2020-09-03
SG11202106353VA (en) 2021-07-29
CN113474359A (zh) 2021-10-01

Similar Documents

Publication Publication Date Title
MA55069A (fr) Nouvelles protéines de fusion spécifique à cd137 et gpc3
MA51291A (fr) Protéines de fusion il-2 fc modifiées
MA53982A (fr) Protéines hétérodimères fusionnées à un fragment fc
DK3830120T3 (da) Hidtil ukendt fusionsprotein specifikt for cd137 og pd-l1
DK4011908T3 (da) Ultralangtidsvirkende insulin-FC-fusionsproteiner og fremgangsmåder til anvendelse deraf
DK3368554T3 (da) Langtidsvirkende fgf21-fusionsproteiner og farmaceutisk sammensætning omfattende samme
MA50942A (fr) Protéines de liaison à l'adn modifiées
DK3280727T3 (da) Enkeltarmede type i- og type ii-receptorfusionsproteiner og anvendelser deraf
DK3298033T4 (da) Sammensætninger og medicinske anvendelser til tcr-reprogrammering under anvendelse af fusionsproteiner
MA50746A (fr) Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive
DK3292137T3 (da) Proteiner specifikke for cd137
DK3292141T3 (da) Fusionsproteiner
DK3565579T3 (da) Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf
MA41313A (fr) Anticorps de liaison de la protéine april modifiés
DK3368655T3 (da) Forbedret proteinekspression og fremgangsmåder dertil
MA47113A (fr) Protéines de liaison à l'antigène anti- neuropiline et leurs méthodés d'utilisation
MA50255A (fr) Protéines de liaison à nkg2d, cd16, et molécule-1 semblable à la lectine de type c (cll-1)
DK4073098T3 (da) Ultralangtidsvirkende insulin-Fc-fusionsproteiner og fremgangsmåder til anvendelse
DK3350334T3 (da) Udtryk af rekombinante proteiner i trichoplusia ni pupper
MA50908A (fr) Formulations de protéines de fusion vegfr-fc
DK3322734T3 (da) Multivalente og multispecifikke DR5-bindende fusionsproteiner
MA52994A (fr) Peptides à chaîne b de relaxine lipidés modifiés et leur utilisation thérapeutique
DK3380119T3 (da) Fmdv- og e2-fusionsproteiner og anvendelser deraf
DK3728288T3 (da) Fremgangsmåder til forbedret fjernelse af urenheder under protein a-kromatografi
DK3307905T3 (da) Rekombinante fusionsproteiner og biblioteker fra immuncellerepertoirer